June 2025, Vol 15, No 6

We have come so far from the local physician who made house calls and was paid in cash or goods. Now, it seems that no matter what a doctor prescribes, there is no shortage of external opinions as to whether that choice was appropriate. Read More ›

Just a decade ago, physicians were spending an average of 8.7 hours per week on administrative tasks such as maintaining patients’ health records, coordinating referrals, and processing claims. That number has more than tripled today to nearly 28 hours a week in some practices. Read More ›

The FDA has approved penpulimab-kcqx (Akeso Biopharma Co, Ltd) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least 1 other previous line of therapy. Read More ›

Officials with the FDA have approved nivolumab (Opdivo; Bristol Myers Squibb) with ipilimumab (Yervoy; Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma, and other updates. Read More ›

Nivolumab (Opdivo; Bristol Myers Squibb) with ipilimumab (Yervoy; Bristol Myers Squibb) is now FDA approved for patients aged ≥12 years with unresectable or metastatic microsatellite instability-high or mismatch repair–deficient colorectal cancer. Read More ›

Officials with the FDA have approved tislelizumab-jsgr (Tevimbra; BeOne Medicines, Ltd, formerly known as BeiGene, Ltd), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express programmed death-ligand 1. Read More ›

Immune checkpoint inhibitors have altered the management of several cancers, including a subset of colorectal cancers characterized by deficient mismatch repair and microsatellite instability. Read More ›

The use of circulating tumor DNA is emerging as a powerful tool in colorectal cancer management, but its potential to address disparities in care remains an ongoing challenge. Read More ›

In 2024, the FDA approved 50 new treatments, highlighting significant advancements in medicine. In addition, that same year ASCO received 7025 abstracts for its scientific program, reflecting an unprecedented pace of innovation and discovery. Read More ›

The participation rate in oncology clinical trials among veterans receiving care within the Department of Veterans Affairs is low, at 2%. Read More ›